ImpactOS
See an example

European Federation of Pharmaceutical Industries and Associations

Trade and business associations · Luxembourg

In these lists: Biggest budgets, Most meetings, Medicines

Declared lobbying cost
€6,000,000 – €6,499,999 Financial year 01/2025-12/2025
Commission meetings
51
Full-time staff on EU lobbying
13.4
European Parliament access passes
11
Registered since
4 Mar 2009
Public records onlyWhat this means

Every profile, record and figure comes from documents published by EU institutions, national authorities, courts, ethics bodies, the EU Transparency Register or established news outlets. We use no leaks, private data or anonymous tips. AI helps us gather and cross-check sources but never decides anyone's guilt: each record keeps its exact legal status and links to its source, so you can check it yourself

Registering is a legal transparency duty, not a sign of wrongdoing. Budgets and meetings show access, not influence on any particular decision. Register figures as declared on 11 Nov 2026

Fields of interest

Budget, Business and industry, Climate action, Competition, Consumers, Customs, Digital economy and society, Employment and social affairs, Environment, External relations, Humanitarian aid and civil protection, Institutional affairs, International co-operation and development, Public health, Research and innovation, Single market, Trade, Trans-European Networks

Medicines and food topics they name

EU medicines law, Orphan and paediatric medicine incentives, Health technology assessment, Antibiotics and antimicrobials

EU laws and policies they declare following14
  • Any health or pharmaceutical policy stemming from the European institutions, such as - but not exclusive - Industrial Policy, Pharmaceutical Strategy, pharmaceutical, orphan and paediatrics legislati…
  • Main EU legislative proposals or policies targeted (a non-exhaustive list)
  • A Pharmaceutical Strategy for Europe – over 50 legislative and non-legislative proposals
  • Directive 2001/83/EC on the Community code relating to medicinal products for human use
  • Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and…
  • Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products.
  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use
  • In addition, we also follow for example:
  • Clinical Trial Regulation
  • EMA Fees Regulation
  • Europe’s Beating Cancer Plan
  • European Health Data Space
  • HERA Regulation
  • SPCs Regulation revision

Meetings with the Commission

Meetings with Commissioners or their Cabinets since 1 December 2024, as the Commission publishes them

  1. With the Cabinet

    Olivér Várhelyi

    Safe Hearts Plan and EU Screening Week

    Published record
  2. With the Cabinet

    Olivér Várhelyi

    Preventive health and early detection

    Published record
  3. With the Commissioner

    Jessika Roswall

    PFAS clean-up High Level dialogue

    Published record
  4. With the Cabinet

    Jessika Roswall

    PFAS clean-up High Level dialogue

    Published record
  5. With the Commissioner

    Olivér Várhelyi

    Health industry roundtable

    Published record
  6. With the Cabinet

    Olivér Várhelyi

    Health industry roundtable

    Published record
  7. With the Commissioner

    Olivér Várhelyi

    Current pharma affairs

    Published record
  8. With the Cabinet

    Olivér Várhelyi

    Current pharma affairs

    Published record
  9. With the Commissioner

    Olivér Várhelyi

    Health industry roundtable

    Published record
  10. With the Cabinet

    Olivér Várhelyi

    Health industry roundtable

    Published record

See all 51 meetings

Official entries

Checked against sources on 11 Nov 2026